Table of Contents
- Trial overview
- Who can participate
- Treatments being compared
- Study phase and design
- What the study measures
Trial overview
The available study of RO7795081 is an interventional study, which means researchers give study treatments and compare results between groups.[1] It is designed for people with type 2 diabetes mellitus (T2D) and is currently Authorised.[1]
Who can participate
The trial is focused on people with type 2 diabetes.[1] The study data do not give more details about age, sex, or other entry rules, so only the condition-based target group can be confirmed from the source.[1]
Treatments being compared
The study compares RO7795081 with placebo and with semaglutide.[1] A placebo is an inactive treatment used to help show whether the study medicine has an effect.[1] The trial record also lists several oral semaglutide dose groups, including Rybelsus 3 mg, 4 mg, 7 mg, 9 mg, and 14 mg tablets, plus an oral GLP-1R agonist capsule listed as CT-996 in the intervention section.[1]
Study phase and design
This is a Phase 2 trial.[1] Phase 2 studies are usually early studies that look more closely at whether a treatment may work and continue to monitor safety.[1] The planned enrollment is 236 people, which means the study aims to include 236 participants.[1]
What the study measures
The main endpoint is the change in HbA1c from baseline at Week 30.[1] HbA1c is a blood test that shows average blood sugar over time, so this endpoint helps researchers see whether RO7795081 improves blood sugar control.[1] The brief summary says the study is evaluating the effect of RO7795081 compared with placebo on HbA1c.[1]
